These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19747426)

  • 1. alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies.
    Ballard C; Jones EL; Londos E; Minthon L; Francis P; Aarsland D
    Int Psychogeriatr; 2010 Mar; 22(2):321-7. PubMed ID: 19747426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
    Kasuga K; Ikeuchi T
    Brain Nerve; 2012 May; 64(5):505-13. PubMed ID: 22570064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M; Londos E; Minthon L; Nielsen HM
    J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice.
    Lilamand M; Clery J; Vrillon A; Mouton-Liger F; Cognat E; Gaubert S; Hourregue C; Martinet M; Dumurgier J; Hugon J; Bouaziz-Amar E; Paquet C
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.
    Spies PE; Melis RJ; Sjögren MJ; Rikkert MG; Verbeek MM
    J Alzheimers Dis; 2009; 16(2):363-9. PubMed ID: 19221426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of cerebrospinal fluid alpha-synuclein in dementia with Lewy body.
    Bousiges O; Blanc F
    Geriatr Psychol Neuropsychiatr Vieil; 2018 Sep; 16(3):305-310. PubMed ID: 30168437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls.
    Viodé A; Epelbaum S; Benyounes I; Verny M; Dubois B; Junot C; Fenaille F; Lamari F; Becher F
    Analyst; 2019 Oct; 144(21):6342-6351. PubMed ID: 31553333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis.
    Lim X; Yeo JM; Green A; Pal S
    Parkinsonism Relat Disord; 2013 Oct; 19(10):851-8. PubMed ID: 23886935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.
    Kapaki E; Paraskevas GP; Emmanouilidou E; Vekrellis K
    PLoS One; 2013; 8(11):e81654. PubMed ID: 24282614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.
    Lerche S; Machetanz G; Wurster I; Roeben B; Zimmermann M; Pilotto A; Preische O; Stransky E; Deuschle C; Hauser AK; Schulte C; Lachmann I; Waniek K; Gasser T; Berg D; Maetzler W; Brockmann K
    Mov Disord; 2019 Jul; 34(7):1069-1073. PubMed ID: 31189032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Bongianni M; Ladogana A; Capaldi S; Klotz S; Baiardi S; Cagnin A; Perra D; Fiorini M; Poleggi A; Legname G; Cattaruzza T; Janes F; Tabaton M; Ghetti B; Monaco S; Kovacs GG; Parchi P; Pocchiari M; Zanusso G
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2120-2126. PubMed ID: 31599499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
    Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I
    J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies: A Systematic Review and Meta-analysis.
    Zhang Q; Li J; Quan W; Liu L; Qin Y; Pei X; Su H; Xu J; Chen J
    Alzheimer Dis Assoc Disord; 2022 Oct-Dec 01; 36(4):368-373. PubMed ID: 36183420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.